BioPharma Dive – AI / Data
AstraZeneca lung drug gets ‘surprise’ win in COPD trials
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.